Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | RHEB | Q15382 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156821 | 0.87 | MTNR1A (0.64) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL10934841 | 0.85 | MTNR1A (0.59) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL24583898 | 0.85 | MTNR1A (0.63) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL24451623 | 0.82 | MTNR1A (0.45) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL13632220 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL27980445 | 0.81 | MTNR1A (0.56) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL24459343 | 0.81 | MTNR1A (0.45) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL19447299 | 0.81 | MTNR1A (0.44) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL24104984 | 0.80 | MTNR1A (0.61) | MTNR1AMTNR1BMEN1KMT2ANPC1 | |
| SCHEMBL28586501 | 0.80 | MTNR1A (0.65) | MTNR1AMTNR1BMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220400673-A1 | METHODS FOR WEED GROWTH CONTROL | Mustgrow Biologics Corp. (CA) | 2022-12-22 | — | — | US | disclosed |
| US-11358953-B2 | Functionalized peptides as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022109755-A1 | METHODS FOR CONTROLLING FUSARIUM WILT OF BANANA PLANTS | Mustgrow Biologics Corp. (CA) | 2022-06-02 | — | — | WO | disclosed |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022082311-A1 | METHODS AND COMPOSITIONS COMPRISING HERBICIDALLY ACTIVE COMPOUNDS AND THIOCYANATE COMPOUNDS FOR CONTROLLING WEED GROWTH | Mustgrow Biologics Corp. (CA) | 2022-04-28 | — | — | WO | disclosed |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2021077214-A1 | METHODS FOR WEED GROWTH CONTROL | Mustgrow Biologics Corp. (CA) | 2021-04-29 | — | — | WO | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| EP-1950200-B1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | LILLY CO ELI (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998047508-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047507-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998042343-A1 | METHOD FOR TREATMENT OF CHRONIC BRONCHITIS | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | MTNR1A 3517/4885MTNR1B 3396/4885MEN1 3626/4885 |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | MTNR1A 4181/4885MTNR1B 3950/4885MEN1 2278/4885 |
| US-20220400673-A1 | METHODS FOR WEED GROWTH CONTROL | TST, NOTUM, GLO1 | MTNR1A 3012/4885MTNR1B 2447/4885MEN1 4209/4885 |
| US-11358953-B2 | Functionalized peptides as antiviral agents | SARS1, VIP, ACE | MTNR1A 3517/4885MTNR1B 3396/4885MEN1 3626/4885 |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | MTNR1A 3984/4885MTNR1B 3919/4885MEN1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.